Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2006

01-11-2006 | Epidemiology

CHEK2 1100delC mutation is frequent among Russian breast cancer patients

Authors: Elena V. Chekmariova, Anna P. Sokolenko, Konstantin G. Buslov, Aglaya G. Iyevleva, Yulia M. Ulibina, Maxim E. Rozanov, Natalia V. Mitiushkina, Alexandr V. Togo, Dmitry E. Matsko, Dmitry A. Voskresenskiy, Oleg L. Chagunava, Peter Devilee, Cees Cornelisse, Vladimir F. Semiglazov, Evgeny N. Imyanitov

Published in: Breast Cancer Research and Treatment | Issue 1/2006

Login to get access
Metadata
Title
CHEK2 1100delC mutation is frequent among Russian breast cancer patients
Authors
Elena V. Chekmariova
Anna P. Sokolenko
Konstantin G. Buslov
Aglaya G. Iyevleva
Yulia M. Ulibina
Maxim E. Rozanov
Natalia V. Mitiushkina
Alexandr V. Togo
Dmitry E. Matsko
Dmitry A. Voskresenskiy
Oleg L. Chagunava
Peter Devilee
Cees Cornelisse
Vladimir F. Semiglazov
Evgeny N. Imyanitov
Publication date
01-11-2006
Published in
Breast Cancer Research and Treatment / Issue 1/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9227-7

Other articles of this Issue 1/2006

Breast Cancer Research and Treatment 1/2006 Go to the issue

Preclinical Study

Secreted Frizzled Related Protein 2 (sFRP2) Decreases Susceptibility to UV-Induced Apoptosis in Primary Culture of Canine Mammary Gland Tumors by NF-κB Activation or JNK Suppression

Clinical Trial

Premature Menopause in Patients with BRCA1 Gene Mutation

Epidemiology

Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer

Epidemiology

Interaction of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferase M1 to breast cancer in Taiwanese woman without smoking and drinking habits

Clinical trial

Estrogen Receptor Expression in Benign Breast Ductal Cells Obtained from Random Periareolar Fine Needle Aspiration Correlates with Menopausal Status and Cytomorphology Index Score

Epidemiology

Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits